{
    "organizations": [],
    "uuid": "c9a7d948d53b0bbe68c39b16dc291158c87d2594",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-magforce-says-receives-fda-investi/brief-magforce-says-receives-fda-investigational-device-exemption-approval-idUSASM000J69",
    "ord_in_thread": 0,
    "title": "BRIEF-Magforce Says Receives FDA Investigational Device Exemption Approval",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - MAGFORCE AG:\n* SAID ON SATURDAY RECEIVED FDA INVESTIGATIONAL DEVICE EXEMPTION APPROVAL TO CONDUCT A CLINICAL TRIAL WITH NANOTHERM THERAPY AS FOCAL ABLATION TREATMENT FOR INTERMEDIATE RISK PROSTATE CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-12T14:42:00.000+02:00",
    "crawled": "2018-02-13T15:53:25.023+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "magforce",
        "ag",
        "said",
        "saturday",
        "received",
        "fda",
        "investigational",
        "device",
        "exemption",
        "approval",
        "conduct",
        "clinical",
        "trial",
        "nanotherm",
        "therapy",
        "focal",
        "ablation",
        "treatment",
        "intermediate",
        "risk",
        "prostate",
        "cancer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}